| Factors determining success and energy requirements for cardioversion of atrial fibrillation. | |
| | |
MedLine Citation:
|
PMID: 2236476 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Factors thought to affect the success of and energy requirements for cardioversion of atrial fibrillation were studied in 80 (49 male, 31 female) patients aged 21-88 (mean 61.5 years). Transthoracic impedance was measured in advance of the countershock using a 30 kHz low amplitude AC current passed through self-adhesive ECG/defibrillator pads (diameters 8-12 cm) applied to the chest in the antero-posterior (AP) position in 57 patients and the anteroapical (AA) position in 23 patients. Mean transthoracic impedance for all patients was 69.3 +/- 16 (SD) ohms (range 39-131 ohms), but transthoracic impedance was significantly greater in the AA than the AP position (75.4 +/- 13 vs. 66.7 +/- 16 ohms, p = 0.02). Initial energy was 50 J (delivered) and was gradually increased to a maximum of 360 J if required. Cardioversion was successful in 73 of 80 (91.2 per cent), and low energy shocks (less than or equal to 200 J) were successful in 45 of 80 (56.2 per cent) patients. Using single factor analysis, sex, left atrial enlargement, electrode pad positions, aetiology of atrial fibrillation, presence of left ventricular failure, and prior treatment with verapamil or beta-adrenergic blockers were not significant determinants of cardioversion success or success of low energy shocks but prior treatment with digoxin was, both for cardioversion success and success at low energies. In patients with transthoracic impedance less than or equal to 70 ohms, low energy shocks were more often successful (33 or 50, 66 per cent) than in patients with transthoracic impedance greater than 70 ohms (12 of 30, 40 per cent), p = 0.04. Using univariate analysis, cardioversion success with low energy shocks was not only significantly associated with prior treatment with digoxin but also with the duration of atrial fibrillation (24 hours to one month and one month to three years) and for shocks of less than or equal to 100 J, with prior treatment with amiodarone. Multifactorial linear regression analysis selected, in rank order, only duration of atrial fibrillation of 24 hours to less than one month and one month to three years as significant predictors of both cardioversion success irrespective of shock strength, and success of low energy shocks. |
| | |
Authors:
|
G W Dalzell; J Anderson; A A Adgey |
Related Documents
:
|
20720486 - Efficacy of hybrid therapy in the form of right atrial ablation and adjunctive therapy ... 21127866 - Comparison of the efficacy of the embolic agents acrylamido polyvinyl alcohol microsphe... 1704596 - Morbidity and mortality of patients with sinus node disease: comparative effects of atr... 17019636 - Long-term single procedure efficacy of catheter ablation of atrial fibrillation. 6146586 - Somatostatin in the treatment of severe gastrointestinal bleeding from peptic origin. a... 20438886 - Do gastrotomies require repair after endoscopic transgastric peritoneoscopy? a controll... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The Quarterly journal of medicine Volume: 76 ISSN: 0033-5622 ISO Abbreviation: Q. J. Med. Publication Date: 1990 Sep |
Date Detail:
|
Created Date: 1990-12-10 Completed Date: 1990-12-10 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0401027 Medline TA: Q J Med Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 903-13 Citation Subset: IM |
Affiliation:
|
Regional Medical Cardiology Centre, Royal Victoria Hospital, Belfast, N. Ireland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Atrial Fibrillation / drug therapy, physiopathology, therapy* Digoxin / therapeutic use Electric Countershock / instrumentation, methods* Electrophysiology Female Humans Male Middle Aged Prospective Studies Regression Analysis Time Factors |
| Chemical | |
Reg. No./Substance:
|
20830-75-5/Digoxin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Psychotherapy of sociopathic and objectively dangerous patients. Psychotherapy of sociopathic patien...
Next Document: Adrenal dysfunction in patients with renal amyloid.